May 15, 2020
Via: The Medical NewsAvacta is developing cancer immunotherapeutics, and diagnostics, based on its Affimer technology. The Affimer® platform is an alternative to antibodies derived from a small human protein, designed to address many of the shortcomings and negative performance issues associated with antibodies, […]
March 28, 2024
April 19, 2024
Copyright © 2024. All rights reserved
